AR036492A1 - Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes - Google Patents
Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientesInfo
- Publication number
- AR036492A1 AR036492A1 ARP020103351A ARP020103351A AR036492A1 AR 036492 A1 AR036492 A1 AR 036492A1 AR P020103351 A ARP020103351 A AR P020103351A AR P020103351 A ARP020103351 A AR P020103351A AR 036492 A1 AR036492 A1 AR 036492A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- aryl
- heteroaryl
- arylalkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000003098 androgen Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101710088194 Dehydrogenase Proteins 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 5
- 125000004104 aryloxy group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 methylenedioxy, difluormethylenedioxy Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 102000054917 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 abstract 1
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto de la fórmula (1) una prodroga del mismo, o una sal o solvato aceptables para uso farmacéutico de dicho compuesto o de dicha prodroga en el cual, R1 y R2 son iguales o diferentes y se seleccionan independientemente del grupo integrado por arilo, heteroarilo, arilalquilo y heteroarilalquilo, cada uno sustituido opcionalmente con 1 a 6 grupos seleccionados del grupo integrado por: halógeno, -OCF3 u -OCHF2, -CF3, -CN, alquilo o R18-alquilo, heteroalquilo o R18-R18-heteroalquilo, arilo o R18-arilo, heteroarilo o R18-heteroarilo, arilalquilo o R18-arilalquilo, heteroarilalquilo o R18-heteroarilalquilo, hidroxi, alcoxi, ariloxi, -SO2-alquilo, -NR11R12, -N(R11)C(O)R13, metilendioxi, difluormetilendioxi, trifluoralcoxi, -SCH3 o -SCF3, y -SO2CF3 ó -NHSO2CF3; R3 es H, -OH, alcoxi o alquilo, con la condición de que cuando X es N, R3 no es -OH ó alcoxi; R4, R5, R7 y R8 son iguales o diferentes y se seleccionan independientemente del grupo integrado por H, -OH, OR14, -NR11R12, -N(R11)C(O)R13, alquilo, heteroalquilo, arilo, cicloalquilo, arilalquilo, heteroarilo, heteroarilalquilo, heterocicloalquilo, fórmula (2), (3) y (4) con la condición de que cuando Z y/o X son N, entonces R4, R5, R7 y R8 no son -OH, -OR14, -NR11R12 ó -N(R11)C(O)R13; R6 se selecciona del grupo integrado por -C(O)R15 y -SO2R15; R9 y R10 son iguales o diferentes y se seleccionan independientemente del grupo integrado por H, F, -CF3, alquilo, cicloalquilo, arilalquilo, heteroalquilo, heteroarilalquilo, heterocicloalquilo, hidroxi, alcoxi, ariloxi, -NR11R12 y -N(R11)C(O)R13, con la condición de que cuando Z es N, entonces R9 y R10 no son F, hidroxi, alcoxi, ariloxi, -NR11R12 ó -N(R11)C(O)R13; R11 se selecciona del grupo integrado por H, alquilo, arilo y heteroarilo; R12 se selecciona del grupo integrado por H, alquilo, arilo y heteroarilo; R13 se selecciona del grupo integrado por alquilo, alcoxi y ariloxi; R14 se selecciona del grupo integrado por H, alquilo, arilo y heteroarilo; R15 se selecciona del grupo integrado por -NR16R17, -OR16, alquilo, cicloalquilo, heterocicloalquilo, arilo, arilalquilo y heteroarilalquilo, cada uno sustituido opcionalmente con R18; R16 y R17 son iguales o diferentes y se seleccionan independientemente del grupo integrado por H, alquilo, arilo, arilalquilo, heteroalquilo y heteroarilo, cada uno sustituido opcionalmente con R18, R18 es uno de 4 sustituyentes seleccionados del grupo integrado por alquilo inferior, halo, ciano, nitro, haloalquilo, hidroxi, alcoxi, alcoxi carbonilo, carboxi, carboxialquilo, carboxamida, mercapto, amino, alquilamino dialquilamino, sulfonilo, sulfonamido, cicloalquilo, heterocicloalquilo, heterocicloalquilalquilo, arilo y heteroarilo; y X y Z son iguales o diferentes y se seleccionan independientemente del grupo integrado por C y N; que son útiles como inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3. También se describen composiciones farmacéuticas que contienen dichos compuestos y su uso en la elaboración de un medicamento para el tratamiento o la prevención de enfermedades andrógeno dependientes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31771501P | 2001-09-06 | 2001-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036492A1 true AR036492A1 (es) | 2004-09-15 |
Family
ID=23234950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103351A AR036492A1 (es) | 2001-09-06 | 2002-09-05 | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US6903102B2 (es) |
| EP (1) | EP1423381B1 (es) |
| JP (1) | JP4320252B2 (es) |
| KR (1) | KR100991616B1 (es) |
| CN (1) | CN1551878B (es) |
| AR (1) | AR036492A1 (es) |
| AT (1) | ATE350375T1 (es) |
| AU (1) | AU2002326823B2 (es) |
| BR (1) | BR0212378A (es) |
| CA (1) | CA2459311C (es) |
| CY (1) | CY1106521T1 (es) |
| DE (1) | DE60217363T2 (es) |
| DK (1) | DK1423381T3 (es) |
| EC (1) | ECSP045004A (es) |
| ES (1) | ES2276950T3 (es) |
| HU (1) | HUP0402629A3 (es) |
| IL (2) | IL160065A0 (es) |
| MX (1) | MXPA04002167A (es) |
| MY (1) | MY141661A (es) |
| NO (1) | NO327254B1 (es) |
| NZ (1) | NZ530810A (es) |
| PE (1) | PE20030703A1 (es) |
| PL (1) | PL369108A1 (es) |
| PT (1) | PT1423381E (es) |
| RU (1) | RU2315763C2 (es) |
| SI (1) | SI1423381T1 (es) |
| TW (1) | TWI329108B (es) |
| WO (1) | WO2003022835A1 (es) |
| ZA (1) | ZA200401456B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1386922B1 (en) | 1996-12-03 | 2012-04-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
| US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
| ES2347643T3 (es) * | 2001-10-17 | 2010-11-03 | Schering Corporation | Piperin- y piperazinacetamidas como inhibidores de 17beta hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgenos. |
| ATE350383T1 (de) | 2002-08-23 | 2007-01-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US7132539B2 (en) * | 2002-10-23 | 2006-11-07 | The Procter & Gamble Company | Melanocortin receptor ligands |
| ES2345146T3 (es) * | 2002-11-18 | 2010-09-16 | Schering Corporation | Inhibidores de 17beta-hidroxiesteroides deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos. |
| AU2003293555A1 (en) | 2002-12-17 | 2004-07-29 | Schering Corporation | 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| US7524853B2 (en) | 2003-06-10 | 2009-04-28 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| US7465739B2 (en) | 2003-06-10 | 2008-12-16 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| US7754709B2 (en) * | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
| TW200528110A (en) * | 2003-12-17 | 2005-09-01 | Schering Corp | Pharmaceutical compositions |
| CN1930181A (zh) | 2004-01-07 | 2007-03-14 | 恩多研究公司 | 螺旋12定向的甾族药品 |
| US7138246B2 (en) | 2004-03-01 | 2006-11-21 | Bristol-Myers Squibb Company | Methods for identifying or screening for agents that modulate 17β-HSD3 |
| US7417040B2 (en) | 2004-03-01 | 2008-08-26 | Bristol-Myers Squibb Company | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7569725B2 (en) | 2004-10-21 | 2009-08-04 | Britsol-Myers Squibb Company | Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| US7615556B2 (en) | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US8884061B2 (en) * | 2006-03-03 | 2014-11-11 | Colorado State University Research Foundation | Compositions and methods of use of electron transport system inhibitors |
| ATE543798T1 (de) * | 2006-04-24 | 2012-02-15 | Lilly Co Eli | Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1 |
| CA2649650C (en) * | 2006-04-24 | 2014-01-14 | Eli Lilly And Company | Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| SG172685A1 (en) * | 2006-06-28 | 2011-07-28 | Amgen Inc | Glycine transporter-1 inhibitors |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| US8080540B2 (en) * | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| US8273883B2 (en) * | 2007-02-09 | 2012-09-25 | Kaneka Corporation | Method for producing optically active 2-arylpiperazine derivative |
| TWI433838B (zh) | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
| US8501940B2 (en) * | 2008-07-15 | 2013-08-06 | Hoffmann-La Roche Inc. | Tetrahydrocinnoline derivatives |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| BR112014003567A2 (pt) | 2011-08-16 | 2018-08-14 | Mt Sinai School Of Medicine | composto, uso de um composto, e, composição farmacêutica |
| EP2961409A1 (en) * | 2013-02-26 | 2016-01-06 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
| TW201512215A (zh) | 2013-06-25 | 2015-04-01 | Forendo Pharma Ltd | 治療活性雌三烯噻唑衍生物 |
| AU2014300894A1 (en) | 2013-06-25 | 2016-01-28 | Forendo Pharma Ltd | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase |
| JP6456373B2 (ja) | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
| MX2016002479A (es) * | 2013-09-12 | 2016-05-31 | Pfizer | Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris. |
| CN103755626A (zh) * | 2014-01-23 | 2014-04-30 | 安徽安腾药业有限责任公司 | 一种贝托斯汀关键中间体的合成方法 |
| FR3017868A1 (fr) * | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US10413557B2 (en) | 2014-12-23 | 2019-09-17 | Forendo Pharma Ltd. | Prodrugs of 17.BETA.-HSD1-inhibitors |
| WO2016102775A1 (en) | 2014-12-23 | 2016-06-30 | Forendo Pharma Ltd | PRODRUGS OF 17β-HSD1 -INHIBITORS |
| WO2018023017A1 (en) | 2016-07-29 | 2018-02-01 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer |
| CN110621669A (zh) | 2017-05-04 | 2019-12-27 | 巴斯夫欧洲公司 | 防除植物病原性真菌的取代5-卤代烷基-5-羟基异噁唑类 |
| SG11201911776PA (en) | 2017-06-08 | 2020-01-30 | Forendo Pharma Ltd | 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases |
| CA3122049C (en) | 2018-12-05 | 2023-10-17 | Forendo Pharma Ltd | Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 |
| MA56457A (fr) | 2019-07-02 | 2022-05-11 | Regeneron Pharma | Modulateurs de hsd17b13 et leurs procédés d'utilisation |
| MX2022002282A (es) | 2019-08-28 | 2022-03-25 | Unilever Ip Holdings B V | Compuestos novedosos para aclarar la piel. |
| CN119143715B (zh) * | 2024-11-12 | 2025-03-14 | 天津匠新致成科技有限公司 | 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3590389T1 (de) | 1984-08-02 | 1986-08-28 | Schering Corp., Kenilworth, N.J. | Pharmazeutische Zusammensetzung für eine Kombinationstherapie hormon-abhängiger Cancer |
| PH30747A (en) | 1989-03-10 | 1997-10-17 | Endorech Inc | Combination therapy for the treatment of estrogen sensitive disease. |
| DK0595796T3 (da) | 1989-07-07 | 2003-05-05 | Endorech Inc | Fremgangsmåde til behandling af androgen-relaterede sygdomme |
| CA2062973C (en) | 1989-07-07 | 2003-09-23 | Fernand Labrie | Combination therapy for prophylaxsis and/or treatment of benign prostatic hyperplasia |
| JP2651043B2 (ja) * | 1990-07-10 | 1997-09-10 | 麒麟麦酒株式会社 | ジフェニルメチルピペラジン誘導体 |
| IL99320A (en) | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical compositions containing them |
| ATE122673T1 (de) * | 1990-10-10 | 1995-06-15 | Schering Corp | Pyridin- und pyridin-n-oxid-derivate von diarylmethyl- piperidinen oder piperazinen, deren zusammensetzungen und anwendung. |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| DE69303605T2 (de) | 1992-03-27 | 1997-01-23 | Schering Corp | Unverbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung |
| EP0666856B1 (en) | 1992-10-28 | 2000-01-05 | MERCK SHARP & DOHME LTD. | 4-arylmethyloxymethyl piperidines as tachykinin antagonists |
| JPH08504435A (ja) | 1992-12-14 | 1996-05-14 | メルク シヤープ エンド ドーム リミテツド | タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン |
| CZ285893B6 (cs) | 1993-05-17 | 1999-11-17 | Endorecherche Inc. | Antiandrogenní sloučenina, její prekursor a farmaceutický prostředek ji obsahující |
| EP0702681A1 (en) | 1993-06-07 | 1996-03-27 | Merck & Co. Inc. | Spiro-substituted azacycles as neurokinin antagonists |
| JPH09507500A (ja) | 1994-01-13 | 1997-07-29 | メルク シヤープ エンド ドーム リミテツド | ｇｅｍ二置換アザシクロ系のタキキニン拮抗薬 |
| US5719156A (en) | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5688960A (en) | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
| US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5654316A (en) | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
| US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
| US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| US5789422A (en) | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
| US5968929A (en) | 1996-10-30 | 1999-10-19 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5945428A (en) | 1996-11-01 | 1999-08-31 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5783579A (en) | 1996-12-20 | 1998-07-21 | Schering Corporation | Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists |
| WO2000017163A1 (en) * | 1998-09-22 | 2000-03-30 | Yamanouchi Pharmaceutical Co., Ltd. | Cyanophenyl derivatives |
| US6063926A (en) | 1998-11-18 | 2000-05-16 | Schering Corporation | Substituted oximes as neurokinin antagonists |
| US6204265B1 (en) | 1998-12-23 | 2001-03-20 | Schering Corporation | Substituted oximes and hydrazones as neurokinin antagonists |
| DE60018707T2 (de) | 1999-01-25 | 2006-02-09 | Smithkline Beecham Corp. | Anti-androgene und verfahren zur behandlung von krankheiten |
| US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| HUP0301391A3 (en) * | 2000-02-11 | 2010-03-29 | Vertex Pharma | Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use |
-
2002
- 2002-09-05 MY MYPI20023327A patent/MY141661A/en unknown
- 2002-09-05 MX MXPA04002167A patent/MXPA04002167A/es active IP Right Grant
- 2002-09-05 TW TW091120285A patent/TWI329108B/zh active
- 2002-09-05 PL PL02369108A patent/PL369108A1/xx not_active Application Discontinuation
- 2002-09-05 AT AT02761567T patent/ATE350375T1/de active
- 2002-09-05 SI SI200230475T patent/SI1423381T1/sl unknown
- 2002-09-05 CA CA2459311A patent/CA2459311C/en not_active Expired - Fee Related
- 2002-09-05 PT PT02761567T patent/PT1423381E/pt unknown
- 2002-09-05 KR KR1020047003247A patent/KR100991616B1/ko not_active Expired - Fee Related
- 2002-09-05 HU HU0402629A patent/HUP0402629A3/hu unknown
- 2002-09-05 DE DE60217363T patent/DE60217363T2/de not_active Expired - Lifetime
- 2002-09-05 RU RU2004110410/04A patent/RU2315763C2/ru not_active IP Right Cessation
- 2002-09-05 AU AU2002326823A patent/AU2002326823B2/en not_active Ceased
- 2002-09-05 EP EP02761567A patent/EP1423381B1/en not_active Expired - Lifetime
- 2002-09-05 NZ NZ530810A patent/NZ530810A/en not_active IP Right Cessation
- 2002-09-05 WO PCT/US2002/028181 patent/WO2003022835A1/en not_active Ceased
- 2002-09-05 BR BR0212378-9A patent/BR0212378A/pt not_active IP Right Cessation
- 2002-09-05 ES ES02761567T patent/ES2276950T3/es not_active Expired - Lifetime
- 2002-09-05 JP JP2003526910A patent/JP4320252B2/ja not_active Expired - Fee Related
- 2002-09-05 AR ARP020103351A patent/AR036492A1/es unknown
- 2002-09-05 CN CN028172507A patent/CN1551878B/zh not_active Expired - Fee Related
- 2002-09-05 PE PE2002000878A patent/PE20030703A1/es not_active Application Discontinuation
- 2002-09-05 DK DK02761567T patent/DK1423381T3/da active
- 2002-09-05 US US10/235,627 patent/US6903102B2/en not_active Expired - Fee Related
- 2002-09-05 IL IL16006502A patent/IL160065A0/xx unknown
-
2004
- 2004-01-26 IL IL160065A patent/IL160065A/en not_active IP Right Cessation
- 2004-02-23 ZA ZA200401456A patent/ZA200401456B/en unknown
- 2004-03-04 EC EC2004005004A patent/ECSP045004A/es unknown
- 2004-04-05 NO NO20041452A patent/NO327254B1/no not_active IP Right Cessation
-
2005
- 2005-01-28 US US11/045,967 patent/US7138396B2/en not_active Expired - Fee Related
- 2005-11-14 US US11/273,712 patent/US7432268B2/en not_active Expired - Fee Related
-
2007
- 2007-03-16 CY CY20071100371T patent/CY1106521T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030703A1 (es) | Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3 | |
| AR036812A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos para el tratamiento de enfermedades androgeno-dependientes | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| NO20080456L (no) | Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer | |
| PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
| AR067443A1 (es) | Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central | |
| AR037355A1 (es) | Compuesto derivado de difenilamina, composicion farmaceutica y su uso en la fabricacion de medicamentos | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| PE20141935A1 (es) | Compuestos de dioxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| AR046046A1 (es) | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. | |
| AR063101A1 (es) | Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2. | |
| SE0202133D0 (sv) | Novel compounds | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| AR049263A1 (es) | Heterociclos biciclicos inhibidores de quinasa utiles como agentes anticancer | |
| CO5650165A2 (es) | Procedimientos para la preparacion de derivados de benzoimidazol | |
| AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
| AR036248A1 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| AR044006A1 (es) | Compuesto de fenilpiperidinilo, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto | |
| AR019789A2 (es) | Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento | |
| AR062499A1 (es) | Derivados de n-fenil pirazol y piridil pirazoles, composiciones farmaceuticas que los contienen y usos como agentes antiagregantes plaquetarios y antitromboticos. | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| AR040247A1 (es) | Derivados de piperazinilacilpiperidina substituidos, su preparacion, composicion farmaceutica y medicamento que lo comprenden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |